All In Biotech

Drug Trial Radar · NCT07024615

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator's Choice of Adjuvant Chemotherapy in Participants With Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Oct 16, 2025

Primary completion

Jan 31, 2028

Study completion Jan 31, 2028

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell called a T-cell. The T-cell "tells" the immune system to attack the tumor. This study is for people with resectable PDAC. Resectable means that the tumor can be removed by surgery. In this study, adults with resectable PDAC will receive an ASP2138 injection just below the skin (subcutaneous) 2 weeks before surgery. After surgery, they will be given standard chemotherapy treatments chosen by their study doctor. These include mFOLFIRINOX, gemcitabine with nab-paclitaxel, or gemcitabine with capecitabine. People will receive chemotherapy treatment for up to 6 months, or until their cancer gets worse, they cannot tolerate the chemotherapy, or they or their study doctor thinks they should stop chemotherapy. People will have a final clinic visit about a month after finishing chemotherapy for health checks.

Conditions

  • Pancreatic Ductal Adenocarcinoma

Interventions

  • ASP2138Drug

    Subcutaneously

  • OxaliplatinDrug

    Injection

  • LeucovorinDrug

    Injection

  • 5-FUDrug

    Injection

  • IrinotecanDrug

    Injection

  • GemcitabineDrug

    Intravenously

  • Nab-paclitaxelDrug

    Intravenously

  • CapecitabineDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs)Time frame: Up to 11.5 months
  2. Number of participants with Serious Adverse Events (SAEs)Time frame: Up to 11.5 months
  3. Number of participants with laboratory value abnormalities and/or AEsTime frame: Up to 11.5 months
  4. Number of participants with vital signs abnormalities and/or AEsTime frame: Up to 11.5 months
  5. Number of participants with 12-lead electrocardiogram (ECG) abnormalities and/or AEsTime frame: Up to 10.5 months
  6. Number of participants with physical examinations (PEs) abnormalities and/or AEsTime frame: Up to 11.5 months
  7. Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status scoreTime frame: Up to 11.5 months
  8. Number of participants with ASP2138-related surgery delays (≥ 7 days)Time frame: Up to 12 weeks after the end of neoadjuvant treatment

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Duke University Medical Center - Duke Cancer Center

    Durham, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.